Climb Bio, Inc. cotiza a 10.31 USD y tiene una capitalización bursátil de $592M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.18 | $-0.20 | $-0.26 |
| Estimado | $-0.19 | $-0.21 | $-0.30 | $-0.21 |
| Sorpresa | — | +14.3% | +33.3% | -23.8% |
| Métrica | CLYM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -37.3% | -40.4% | +3.1% |
| ROA | -35.7% | -32.0% | -3.7% |
| Current Ratio | 15.16 | 2.84 | +12.32 |
| Debt / Equity | — | 0.28 | — |